Jane Lebkowski, President & CSO, Regenerative Patch Tech. at Stem Cell Conf. (Oct 24-26, 2012 in PA)
Jane Lebkowski, President & Chief Scientific Officer, Regenerative Patch Technologies (Former VP & CSO, Geron) to Discuss "iPS & hESC Sourced Pluripotent Cells: Best Uses for Each Technology" at the 9th Stem Cell Research & Therapeutics Conference (Oct 24-26, 2012 in Philadelphia, PA).
- San Francisco, CA (1888PressRelease) August 09, 2012 - A panel of experts will discuss "iPS & hESC Sourced Pluripotent Cells: Best Uses for Each Technology", and will cover topic areas on the uses of iPS and hESC cells for drug discovery and development.
Areas of discussion include: the validation of use of iPS and hESC sources to discriminate potential toxicities associated with drugs; validation of iPS cells as models for human disease; validation of use of iPS cells to elucidate targets associated with human disease; Suitability of hESC and iPS cells for allogeneic cell-based Therapies; Suitability of iPS Cells for Autologous Cell-Based Therapies; Therapeutic Indications where iPS and hESC-based Cell Therapies Could Be Practica; Preclinical Testing of iPS and hESC cell Therapeutics.
Distinguished panelists includes: 1). Jane Lebkowski, President & Chief Scientific Officer at Regenerative Patch Technologies and Former Vice President & CSO at Geron 2). Chris Parker, Chief Commercial Officer at Cellular Dynamics International 3). Casey Case, Vice President of Research at SanBio. Others will be announced.
This year's Keynote Presentation Speakers include: Eduardo Marban, Director & Mark S. Siegel Family Professor at Cedars-Sinai Heart Institute and Randal Mills, President & Chief Executive Office at Osiris.
GTC's 9th Stem Cell Research & Therapeutics Conference, taking place on October 24-26, 2012 in Philadelphia, PA presents information regarding cutting-edge developments in all areas of stem cell research including the biology, medicine, applications and regulations of stem cells. Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming will be addressed.
Presenting will be Top Executive Speakers from the following Companies: Osiris, ATRM, a Johnson & Johnson Company, Angiocrine Bioscience, Athersys, Bioheart, Capricor, Celgene, Cellectis Stem Cells, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, NIH, Pfizer, Pluristem, Regenerative Patch Technologies, Roche, SanBio, Tengion, and many more!
To view the Program Agenda Click Here. To view the Speaker List Click Here.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam